Raspollini Maria Rosaria, Amunni Gianni, Villanucci Alessandro, Boddi Vieri, Taddei Gian Luigi
Department of Human Pathology and Oncology, School of Medicine, University of Florence, Italy.
Acta Obstet Gynecol Scand. 2006;85(4):493-8. doi: 10.1080/00016340500438173.
CA-125 is elevated in the serum of the majority of ovarian carcinoma patients. Cyclooxygenase-2 is an enzyme whose synthesis is upgraded by several cytokines, growth factors, and tumor promoters.
We analyzed cyclooxygenase-2, preoperative CA-125 levels, and CA-125 levels during chemotherapy in 41 FIGO stage III, grade 3, ovarian serous carcinoma patients in relation to survival with a logistic regression. The correlation of cyclooxygenase-2 expression and CA-125 preoperative level with clinical responsiveness to chemotherapy was studied according to Fisher's exact test. We compared 23 patients living with no evident disease five years after primary treatment to 18 patients who had died of progression of disease no later than two years after primary treatment.
Cyclooxygenase-2 overexpression (p = 0.014 and p = 0.036) and preoperative CA-125 level (p = 0.012 and p = 0.029) were found to be independent predictors of survival in univariate and multivariate analyses. Cyclooxygenase-2 and CA-125 level were correlated to responsiveness to chemotherapy (p = 0.003 and p = 0.036, respectively; Fisher's exact test). The patients with a CA-125 level <35 U/ml after two cycles of chemotherapy showed a longer survival (p = 0.008). The median preoperative CA-125 was 195 in high survival patients and 650 in low survival patients (p= 0.004, Wilcoxon Mann-Whitney test).
Cyclooxygenase-2 overexpression and CA-125 levels may help the management of ovarian cancer patients, permitting the selection of more aggressive and tailored first-line therapy.
大多数卵巢癌患者血清中的CA - 125水平会升高。环氧合酶 - 2是一种其合成会被多种细胞因子、生长因子和肿瘤启动子上调的酶。
我们对41例国际妇产科联盟（FIGO）III期、3级卵巢浆液性癌患者的环氧合酶 - 2、术前CA - 125水平以及化疗期间的CA - 125水平进行分析，通过逻辑回归分析其与生存的关系。根据费舍尔精确检验研究环氧合酶 - 2表达和术前CA - 125水平与化疗临床反应性的相关性。我们将23例初次治疗后五年无明显疾病存活的患者与18例初次治疗后不超过两年死于疾病进展的患者进行比较。
在单因素和多因素分析中，环氧合酶 - 2过表达（p = 0.014和p = 0.036）以及术前CA - 125水平（p = 0.012和p = 0.029）被发现是生存的独立预测因素。环氧合酶 - 2和CA - 125水平与化疗反应性相关（分别为p = 0.003和p = 0.036；费舍尔精确检验）。化疗两个周期后CA - 125水平<35 U/ml的患者生存期更长（p = 0.008）。高生存患者术前CA - 125的中位数为195，低生存患者为650（p = 0.004，威尔科克森秩和检验）。
环氧合酶 - 2过表达和CA - 125水平可能有助于卵巢癌患者的管理，从而允许选择更积极且更具针对性的一线治疗方案。
